Appraisal of Gilenya® (fingolimod) by NICE begins

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Appraisal of Gilenya® (fingolimod) by NICE begins

Postby MSUK » Fri Jul 08, 2011 1:06 am


NICE (The National Institute for Health and Clinical Excellence) has begun its appraisal of Gilenya® (fingolimod), a new oral medication for relapsing-remitting Multiple Sclerosis.

Fingolimod was granted a licence by the EMA (European Medicines Agency) in March 2011. The appraisal by NICE is to decide whether it should be funded by the NHS.

Gilenya® (fingolimod) is the first in a new class of disease-modifying treatments called sphingosine 1-phosphate receptor (S1P-R) modulators and has a novel mode of action different from all currently marketed MS therapies.... Read More - ... ageid/1309
User avatar
Family Elder
Posts: 2501
Joined: Wed Oct 14, 2009 2:00 pm


Return to Gilenya


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service